Amyloid-β Oligomer Biology in Alzheimer's Disease

In Alzheimer’s disease, soluble assemblies of amyloid-β peptides, known as oligomers, represent the earliest neurotoxic species. These oligomers display considerable heterogeneity in size and structure, with distinct conformers exerting differential effects on neuronal function. By binding to specific synaptic receptors—including cellular prion protein and metabotropic glutamate receptor 5—they hijack intracellular signalling pathways such as Fyn kinase activation and disrupt calcium homeostasis. The resultant imbalance between long-term potentiation and long-term depression undermines synaptic plasticity, leading to synapse loss and cognitive decline. Concurrent tau hyperphosphorylation and glial activation exacerbate neuronal damage and fuel a self-amplifying cycle of protein aggregation and neuroinflammation. Deciphering the precise molecular architecture of oligomers and their receptor interactions is critical for the development of targeted interventions that neutralise toxic species while preserving normal peptide function.

Research from Nature Portfolio

Recent studies have uncovered a pivotal role for metabotropic glutamate receptor 5 in Aβ oligomer-induced synaptic depression. Soluble oligomers co-opt this receptor together with prion protein to facilitate long-term depression in vivo, revealing an NMDAR-independent mechanism of synaptic weakening. Another foundational investigation identified discrete nanotubular assemblies of amyloid-β that bind prion protein with high affinity, correlating with inhibition of long-term potentiation. These findings delineate specific oligomer conformations and receptor complexes as drivers of synaptic dysfunction.

Amyloid-β Oligomer Biology in Alzheimer's Disease publication trend

The graph below shows the total number of articles in amyloid-β oligomer biology in alzheimer's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Amyloid-β oligomer (Aβo): A small, soluble aggregate of amyloid-β peptides implicated in synaptic toxicity.

Cellular prion protein (PrPC): A GPI-anchored neuronal surface protein that binds Aβ oligomers to mediate toxicity.

Metabotropic glutamate receptor 5 (mGluR5): A G-protein-coupled receptor involved in Aβ oligomer-induced synaptic depression.

Long-term potentiation (LTP): A enduring increase in synaptic strength underlying learning and memory.

Long-term depression (LTD): A persistent decrease in synaptic efficacy often enhanced by Aβ oligomers.

Fyn kinase: A Src family tyrosine kinase activated downstream of oligomer-receptor interactions.

References

1. Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease. Acta Neuropathologica (2024).
2. Neuronal transcriptome, tau and synapse loss in Alzheimer’s knock-in mice require prion protein. Alzheimer's Research & Therapy (2023).
3. Peptide aptamer targeting Aβ–PrP–Fyn axis reduces Alzheimer’s disease pathologies in 5XFAD transgenic mouse model. Cellular and Molecular Life Sciences (2023).
4. mGlu5 receptors and cellular prion protein mediate amyloid-β-facilitated synaptic long-term depression in vivo. Nature Communications (2014).
5. Amyloid-β nanotubes are associated with prion protein-dependent synaptotoxicity. Nature Communications (2013).